Seeking Alpha

larry luv

larry luv
Send Message
View as an RSS Feed
View larry luv's Comments BY TICKER:
Latest  |  Highest rated
  • Antares Pharma: A Promising Pharmaceutical Play [View article]
    Safety Profile looks great and will probably continue to be once results announced for Libigel next year.The BIG hurdle is efficacy-safety means squat if efficacy is not there.
    So as long as efficacy data is just as good as the Phase2,then this is a homerun for Biosante and Antares....
    CEO of Antares actually hinted that Libigel Efficacy results may come as early as this fall,before the anticipated December timeline..
    Antares has European rights to Libigel and the Worldwide Manufacturing rights,also they get sales royalties and milestones here in the USA..
    Then add their numerous other partnerships and products in their portfolio and Antares has a Strong' possibility of being a huge success story in 2012..
    Aug 19 12:36 PM | Likes Like |Link to Comment
  • 3 Stocks That I'm Bearish On but Refuse to Short [View article]
    what's dat smell?
    Aug 17 10:57 PM | Likes Like |Link to Comment
  • Health Care Stock Watch: Some Stocks Rebounding, Some Not So Much [View article]
    TTNP.OB-Company will be almost cash poor in December.
    Very surprised no partnership by now...
    What gives? Institutions and insiders also not buying yet'
    Phase 3 was a success and you would think a big Pharma would be salivating to partner with Titan, not the case.Good buy at 1.80 or wait til 1.40 to buy more if no deal soon?
    Any thoughts? No real interest by the Street in this novel approach of a 6 month implant-
    go figure.
    Disclosure. Long TTNP.OB
    Aug 17 04:01 PM | Likes Like |Link to Comment
  • Fire Sale on 5 Speculative Healthcare Stocks [View article]
    If I am not mistaken,doesnt Antares own the Worldwide Manufacturing rights to Libigel?
    So if that's the case,not only does Antares get 5.5% from Biosante for US Libigel sales,they would also get manufacturing royalties as not yet negotiated.
    Also,Antares will get upfront and milestone fees if/when Biosante partners Libigel in the US.
    With Antares owning all EX-US rights to Libigel,this puts them in a position for a HUGE payday..
    Now even Excluding potential of Libigel, all the other products in Antares's pipeline makes AIS an excellent stock to load up if u can get it under 2.50
    I think this has a great shot to triple in share price within 3 months.
    PS.In latest CC,the CEO hinted that Antares is coming out with another new product they plan to run trials and bring to market and will announce this quarter... It just doesnt stop for Antares.moving forward' $$$
    Stay tuned
    Aug 15 06:06 PM | Likes Like |Link to Comment
  • 4 Biotech Sleepers With Over 100% Upside [View article]
    I agree IGXT is still bullish and the chart looks good at these current prices.I was just pointing out the discrepancy in company saying this is a 150millon market and their own presentation predicting small scale revenues for the drug.
    Aug 14 12:34 PM | Likes Like |Link to Comment
  • Rapidly Rising Biotech, Pharmaceutical Companies With Big Potential [View article]
    IGXT looks like a nice pre-PDUFA play.
    I bought in.60's and will expect 1.00+ then im out!
    Potential of this drug is confusing, as you hear estimates of 150million-250mil market yet Company's own recent investor presentation puts future revenues of cpi-300 at 2 million to 8 million yearly in their own Pro-Forma Chart...Check out Company presentation at their website.
    What gives?
    Aug 13 01:58 PM | Likes Like |Link to Comment
  • New Developments Could Propel Star Scientific Shares Higher [View article]
    I am amazed by the anti viral properties of this company's jock itch formula-
    Not only can alzeheimer's be cured but the groin area itching stops too';
    Amazing I say'- Put that tobacco in your pipe son'
    Aug 7 10:06 AM | Likes Like |Link to Comment
  • 2 Beaten Up Stocks Are Significantly Under Analysts' Price Targets [View article]
    The prognostications for a bell curve in the adjusted gross analytical credum, can create huge bargains for sentis -related stocks that show growth at a mentistical paradigm .
    Aug 6 10:09 AM | Likes Like |Link to Comment
  • Neoprobe: Why I'm Closing My Short Position [View article]
    Why stop now?
    Especially with a depressed market lately?
    Quite odd indeed.
    Aug 5 11:27 AM | Likes Like |Link to Comment
  • What to Expect From Avanir Pharmaceuticals' Earnings Report Monday [View article]
    What are you getting at with this odd article?
    Nuedexta is the driving force behind the success of this stock and company-
    We need to be looking at the increase in prescriptions and any guidance management gives us.
    Aug 4 05:06 PM | Likes Like |Link to Comment
  • 3 Falling Healthcare Stocks Worth Eyeballing [View article]
    You need to be honest.
    You dont need me to tell you that Deerfield gets 2.5% from Titan's 8% on Fanapt.
    Aug 4 02:17 PM | Likes Like |Link to Comment
  • IntelGenx: Approval is Expected, Significant Upside Ahead [View instapost]
    Page 20 of company presentation
    They lowered their CPI300 revenue projections.
    2013-3 million
    2015-8 million
    any concern?
    Aug 4 09:28 AM | Likes Like |Link to Comment
  • 4 Biotech Sleepers With Over 100% Upside [View article]
    ben_yoffe go to page 20 of that presentation-
    Company gives projections for all their products
    CPI300-It was actually worse than I first wrote!
    2013-3 million
    2014-5 million
    2015- 8 million
    let me know if you found the chart.
    These are miniscule numbers dont ya think?
    Aug 4 09:24 AM | Likes Like |Link to Comment
  • 4 Biotech Sleepers With Over 100% Upside [View article]
    Goes to show you what Company really thinks of their product.
    They obviously dont expect it to capture a big market.
    The company presentation chart which can be viewed at their website, predicts only 10 million dollars in yearly revenues for CPI300.
    I am not sure that includes what their actual revenue cut will be because as you know,they are seeking a partner for CPI300 which would give them just a percentage of sales royalties on that 10 million in yearly revenue projection..
    PS. Unless thats a misprint and thet meant to say 100 million revenues,not 10 million..
    Aug 3 08:25 AM | Likes Like |Link to Comment
  • 4 Biotech Sleepers With Over 100% Upside [View article]
    IGXT's drug CPI-300 that await's FDA Approval is not a blockbuster according to company' own investor presentation!
    Go to their website and see their revenue chart for this drug.
    They expect ONLY 10 MILLION in yearly revenues for this product!
    Where is the value in this company?
    They promise a partnership for CPI-300 but with such low expectations for revenues,where is the upside?
    Now of course with a PDUFA for November,stock can always do a typical runup towards a binary event and many investors can possibly make money that way-Stock probably goes over 1.00 before November, but that could be short lived..
    Aug 1 07:10 AM | Likes Like |Link to Comment